Milan, Italy – March 16, 2026 – In a landmark development set to fundamentally reshape the global hearing care industry, Amplifon, the world’s largest pure-play hearing aid retailer, today announced a definitive agreement to acquire GN Hearing from GN Store Nord. The transaction, valued at approximately €2.3 billion (US$2.64 billion) on a cash-free, debt-free basis, represents a strategic pivot for both companies and is poised to create a vertically integrated audiology powerhouse with unparalleled reach and capabilities.
The proposed acquisition marks Amplifon’s most significant strategic move in its 75-year history, transforming the Italian-based retail giant into a comprehensive player spanning product development, manufacturing, and global patient care. Historically, Amplifon has focused on dispensing hearing devices through its extensive network of clinics under brands like Amplifon and Miracle-Ear, largely avoiding direct manufacturing. This acquisition signifies a profound shift in that long-standing strategy, bringing one of the industry’s top manufacturers, GN Hearing, under its umbrella.
A New Vertically Integrated Leader Emerges
If successfully completed – a process that involves several regulatory and logistical hurdles – the merger would combine Amplifon’s vast retail footprint and clinical expertise with GN Hearing’s robust manufacturing capabilities and innovative technology portfolio. GN Hearing, estimated to be the fourth-largest hearing aid company globally, is renowned for its ReSound, Jabra Enhance, and Beltone hearing aid brands, and has been a significant external supplier to Amplifon, alongside other industry leaders such as Sonova, Demant, and Starkey.
The combined entity is projected to achieve approximately €3.3 billion (US$3.79 billion) in annual revenue, operating in over 100 countries. This scale would position the new group as a formidable force in the audiology sector, boasting more than 20,000 employees, over 700 dedicated R&D professionals, and an impressive patent portfolio exceeding 2,800 patents. This integration is expected to unlock significant opportunities for innovation, enhanced patient solutions, and optimized distribution channels.
Amplifon’s Strategic Imperatives: Innovation and Market Leadership
For Amplifon, this acquisition is a direct response to the evolving dynamics of the hearing care market, characterized by increasing demand for advanced solutions and the growing importance of vertical integration. The company’s Chairperson, Susan Carol Holland, articulated the long-term vision behind the deal, stating, "Today we celebrate the realization of a dream that strengthens our ambition: to integrate technology and innovation with our deep understanding of patients for the benefit of hearing care professionals and the people they serve with empathy and dedication. This milestone allows us to pursue even more effectively the mission with which my family founded Amplifon over 75 years ago, and has guided its growth ever since: to provide outstanding care to a growing number of people, helping them rediscover the full emotions of sound and live their lives to the fullest."
Amplifon CEO Enrico Vita underscored the transformative nature of the acquisition. "Today marks a turning point for Amplifon," he affirmed. "We are announcing the most transformative acquisition in our 75-year-long history, that will fundamentally change the future of the hearing care industry worldwide and create significant and long-term value for all our stakeholders… At a time of significant technological advancements, this combination positions us to set new and higher standards in the audiology industry and allows us to better capture the secular growth trends."
The strategic rationale for Amplifon is multi-faceted:
)
- Vertical Integration: Moving from a pure-play retailer to an integrated model, controlling both product development and distribution.
- Enhanced Innovation: Leveraging GN Hearing’s R&D platform to develop cutting-edge hearing solutions tailored to patient needs.
- Broader Product Portfolio: Expanding the range of solutions available to patients and hearing care professionals under one roof.
- Market Leadership: Solidifying its position as a global leader in audiology by combining retail scale with manufacturing prowess.
- Operational Synergies: Amplifon anticipates realizing €60 million to €80 million (approximately US$69 million to US$92 million) in net EBITDA synergies by the end of 2029, primarily through volume insourcing. Additional synergy opportunities are also being explored.
Amplifon has also committed to preserving GN Hearing’s core identity, brands (including ReSound, Beltone, Interton, Danavox, Jabra Enhance, and Danalogic), and capabilities within the combined organization, signaling a strategy of leveraging established brand equity and technological expertise.
GN Store Nord’s Strategic Realignment: Focus on Audio and Video Peripherals
For GN Store Nord, the divestiture of its hearing business represents a significant strategic reset, allowing the Danish technology group to sharpen its focus on its rapidly expanding audio and video peripherals division. This segment includes premium brands and technologies in areas such as sound processing and low-power edge AI, where GN sees substantial room for growth.
Peter Karlströmer, GN Group CEO, articulated the rationale behind the sale: "We are today acting on an opportunity to create a global leader in hearing care together with Amplifon. Together we are well positioned to develop into an industry leader, driving further innovation and benefits to our industry. For GN, this also creates an opportunity to strengthen our position in the large and attractive audio and video peripherals markets. We have unique brands, talents and capabilities, and a rich set of opportunities. This is very exciting for GN’s customers, investors, and employees working in Hearing and the rest of GN."
The proceeds from the €2.3 billion transaction are expected to exceed GN Store Nord’s net interest-bearing debt, enabling the company to significantly reduce its leverage, invest further in its remaining core businesses, and potentially return capital to shareholders. The carve-out of GN Hearing involves approximately 5,500 employees worldwide, encompassing all hearing-related intellectual property, R&D, manufacturing, and operations, as well as existing Beltone network partnerships. Notably, GN’s approximately 19% financial investment in NationsBenefits LLC is not included in this deal.
)
Financial Structure and Outlook
The acquisition, valued at approximately €2.3 billion, will see GN Store Nord receive €1.69 billion (US$1.94 billion) in cash and 56 million Amplifon shares at closing. This arrangement will make GN a strategic shareholder in Amplifon, holding an approximately 16% stake on a pro-forma basis, assuming a planned equity raise. If no equity raise is completed, GN’s ownership at closing could be around 19.8%. These shares will be subject to customary lock-up and transfer restrictions.
To finance the cash component of the acquisition, Amplifon plans to utilize a bridge loan, which it intends to refinance over time through a combination of debt and equity and/or equity-linked instruments. The company projects that its pro-forma net debt to adjusted EBITDA ratio will be approximately 3.0x at closing, excluding net synergies and assuming an equity raise of up to €0.75 billion (US$860 million). The new group is expected to deleverage over the subsequent two to three years through robust cash generation.
Based on 2025 results, Amplifon estimates the combined business would generate a pro-forma adjusted EBITDA of approximately €830 million (US$952.5 million), including expected run-rate synergies, with a margin of roughly 25%. The transaction is anticipated to be accretive to revenue growth, profitability, and earnings, creating a more balanced mix between retail and service revenue on one side and technology and product revenue on the other.
Regulatory and Shareholder Hurdles Ahead
)
While the boards of both companies have approved the transaction, several significant hurdles remain before the deal can close, which is currently expected by the end of 2026. These include customary regulatory and antitrust approvals across various jurisdictions.
Perhaps the most complex aspect is the required carve-out of GN Hearing from the broader GN Group. This separation will involve a statutory demerger under Danish company law, a process more intricate than a straightforward asset sale.
An additional factor to monitor is GN Store Nord’s shareholder base. Demant, the parent company of Oticon and a major hearing care retailer through brands like HearingLife, Hidden Hearing, and KIND, holds approximately 12% of GN’s shares and votes. While GN’s board has approved the transaction, Demant’s dual role as a significant shareholder and a direct industry competitor adds an interesting dynamic to the approval process. Furthermore, a shareholders’ agreement between GN and Ampliter (Amplifon’s controlling shareholder) is expected, which would grant GN the right to nominate a representative to Amplifon’s board.
Impact on the Global Hearing Aid Market
This acquisition, which would likely rank as the largest "straight acquisition" in the hearing industry’s history (though smaller than the overall transaction value of the 2018 Sivantos-Widex merger), is set to profoundly reshape the competitive landscape. The trend towards vertical integration has been a hallmark of the hearing care sector in recent years, as companies seek to control more of the value chain from manufacturing to patient dispensing. This deal accelerates that trend, creating a powerful new player that could challenge the traditional market leaders.
)
GN Hearing’s robust engineering base and manufacturing footprint in Denmark, China, Malaysia, and the United States provide a strong foundation for continued product innovation. For fiscal year 2025, GN Hearing reported revenues of DKK 7.2 billion (US$1.1 billion), with a significant global presence: 49% of revenue from the Americas, 28% from Europe, and 23% from the rest of the world. Its pro forma, carved-out adjusted EBITDA for 2025 was approximately €220 million (US$252.5 million).
The combination of Amplifon’s extensive clinic network and patient data with GN Hearing’s technological prowess promises to foster an environment ripe for innovation, potentially leading to more personalized and effective hearing solutions for millions worldwide. However, the consolidation also raises questions about market competition and the potential impact on smaller independent retailers and other manufacturers in an increasingly concentrated industry.
As the transaction moves towards its anticipated closing at the end of 2026, all eyes will be on the regulatory bodies and the strategic maneuvers of competitors in this rapidly evolving global hearing care market. The integration of Amplifon and GN Hearing is poised to redefine standards, drive innovation, and ultimately influence the future of hearing health for countless individuals.